medical device investing Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting
medical device investing Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results
medical device investing Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026
medical device investing Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
medical device investing Pulse Biosciences' nPulse Technology to be Featured at the 21st Annual International VT Symposium 2026
medical device investing Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation Treatment
medical device investing Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
medical device investing Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
medical device investing Pulse Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
medical device investing Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
medical device investing Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
medical device investing Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
medical device investing ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
